Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma ... although the picture may not be ...

Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category, cosibelimab, just got knocked back even further after it was turned down by the FDA as a treatment for skin cancer.

Patients with primary Merkel cell carcinoma are at an increased risk of developing a secondary skin cancer vs other malignancies.

Oral squamous cell carcinoma (OSCC) is a leading cause of cancer-related deaths, and early detection is key to improving patient outcomes. However, the mechanisms driving the transition from ...

A new study published in Engineering has identified enolase 2 (ENO2) as a key factor in the lymphatic metastasis of head and neck squamous cell ...

Discovery Reveals Protein Involved in Parkinson's Disease Also Drives Skin Cancer Apr. 9 ... uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five ...

Mature tertiary lymphoid structures evoke intra-tumoral T and B cell responses via progenitor exhausted CD4 + T cells in head and neck cancer The reason of mature tertiary lymphoid structures ...

basal cell carcinoma (BCCs) squamous cell carcinoma (SCCs) melanoma. BCCs and SCCs are different from melanoma. They are called non-melanoma skin cancers and are more common than melanoma. What is the ...